Citations

Clear

1434 citation(s) found for "Uk, Nathan".

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)
Shao, Xiangqiang , Mani, Coumarane, He, Rong , Danos, Arpad , Sheta, Lana , Terraf, Panieh, Raca, Gordana , Williams, Heather , Blombery, Piers , Viswanatha, David S., Jiang, Nan , Vavra, Kevin C., Zhang, Liying , Li, Yuwen , Zhong, Yiming , Matthew, Mariam T, Deeb, Kristin K. , Zhang, Fengli , Liu, Jie , Zhao, Xiaonan, Kopp, Nathan , Pondugula, Santhi , Fakim, Yasmina Jaufeerally , Wu, David , Pullarkat, Sheeja T. , Kulkarni, Shashikant , Madhavan, Subha , Kanagal‐Shamanna, Rashmi , Xu, Xinjie , Kanagal-Shamanna, Rashmi , Rao, Shruti , Saliba, Jason , Kesserwan, Chimene A. , Eno, Celeste , Jiang, Nan, Shi, Zonggao , Li, Peng , Ouseph, Madhu M. , Thompson, Ella R. , Krysiak, Kilannin , Wagner, Alex H. , McCoy, Matthew , Zhao, Xiaonan, Ferrer, Alejandro , Zhang, Wenying , Griffith, Obi L. , Griffith, Malachi

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 4387-4387

10.1182/blood-2021-153546 Get It

Abstract Clinical significance of somatic gene variants needs to be comprehensively characterized for their diagnostic, prognostic and/or therapeutic actionability in patient management. However, challenges remain due to discrepancies in interpretation and reporting of these somatic variants among different testing labs. Therefore, standardized curation, clinical interpretation and reporting of somatic variants in hematologic cancers is critical. To address this issue, the Hematologic Cancer Taskforce (HCT), composed of 52 multi-disciplinary experts including oncologists, molecular pathologists, lab directors, genomic scientists and biocurators, was formed in January 2020 within the ClinGen Somatic Cancer Clinical Domain Working Group (CDWG) with a goal to undertake systematic curation and evidence-based clinical interpretation of genes/somatic variants associated with hematologic malignancies. In collaboration with the Clinical Interpretation of Variants in Cancer (CIViC) (civicdb.org) knowledgebase, HCT members curate, edit, and verify Evidence Items for each variant extracted from peer-reviewed publications. Monthly discussions based on these Evidence Items lead to the preparation of variant Assertions, which summarize the state of the field consensus variant interpretation and include tiering based on the AMP/ASCO/CAP guidelines (PMID: 27993330). FMS-like tyrosine kinase 3 (FLT3) encodes a class III receptor tyrosine kinase expressed in hematopoietic cells. FLT3 mutations, including both internal tandem duplication (ITD) and mutations in the tyrosine kinase domain (TKD), are the most common mutations in acute myeloid leukemia (AML), occurring in approximately 30% of all AML cases. Implementing FLT3 tyrosine kinase inhibitors (TKIs) in different treatment regimens for FLT3 mutated AML patients has led to significantly improved overall survival. Type I FLT3 inhibitors, including midostaurin, gilteritinib, sunitinib, lestaurtinib, and crenolanib, bind to the ATP-binding site when the receptor is in active conformation. Type II FLT3 inhibitors, including sorafenib, ponatinib, and quizartinib, interact with a hydrophobic region directly adjacent to the ATP-binding domain that is only accessible when the receptor is inactive, which prevents receptor activation. Generally in AML cells, type I FLT3 inhibitors prevent activity for both ITD and TKD mutations, while Type II inhibitors target ITD but lack efficiency against TKD mutations. The development of TKD mutations in AML cells with ITD have proved to be a mechanism of acquired, or secondary resistance to Type II FLT3 inhibitors. The HCT is piloting curation assessments of FLT3 alterations, including ITD, TKD and non-TKD variants, in AML. So far, the HCT has curated 75 evidence items for FLT3 somatic variants. FLT3-ITD, as well as D835 and I836 were asserted as tier 1 level A variants based on the prediction of response to gilteritinib in relapsed/refractory AML (PMIDs: 27993330, 31665578, 28645776, 28516360, 27908881). Recent curation activities are focused on FLT3 D839G and N676K, as clinical trials using large AML patient cohorts are lacking in their ability to validate drug response/resistance associations of these two TKD variants due to their low frequency. Functional studies showed both variants result in increased proliferation and protection from apoptosis, supporting the oncogenic potential of these two variants (PMIDs: 26891877, 2468088). FLT3 D839G combined with ITD confers resistance to pexidartinib and ponatinib, both Type II FLT3 inhibitors (PMIDs: 25847190, 23430109). FLT3 N676K predicts response to the Type I FLT3 inhibitor, gilteritinib, when N676K is present alone or in combination with ITD. Interestingly, FLT3 N676K in the absence of ITD predicts response to sorafenib, a Type II FLT3 inhibitor (PMIDs: 32040554, 32984009). However, these results are mostly derived from in vitro studies. Two separate Tier II, Level D Assertions have been submitted for FLT3-ITD&D839G for its response to pexidartinib and ponatinib, and more evidence is being collected to form an Assertion for FLT3 N676K. The complexity of the prediction of response/resistance associated with FLT3 D839G and N676K supports the importance of evidence-based curation and collection for these variants in the context of the overall mutation profile, disease context and specific FLT3 TKIs to clearly define their clinical impact. Disclosures Pullarkat: Stemline Therapeutics: Honoraria.
Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis
Logan, Brent R. , Bo‐Subait, Stephanie, Beitingjaneh, Amer, Farhadfar, Nosha , Gowda, Lohith , Hashmi, Shahrukh K. , Nathan, Sunita , Stefanski, Heather E. , Hsu, Jack W., Panch, Sandhya R. , Shaw, Bronwen E. , Murthy, Guru Subramanian Guru , Devine, Steven M. , Lazarus, Hillard M. , Sharma, Akshay , Yared, Jean A. , Pulsipher, Michael A. , Switzer, Galen E.

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 907-907

10.1182/blood-2021-150635 Get It

Abstract Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). While many factors influence the outcomes of allo-HCT in these leukemias, the independent impact of ABO mismatching between the patient and donor remains unclear. Methods: Using the CIBMTR database, we identified adults aged ≥18 years with AML or ALL who underwent allo-HCT from HLA-matched sibling donor (MSD) or 8/8 matched unrelated donor (MUD) between 2008-2018. We excluded patients who underwent transplant from a mismatched donor source or who received an ex-vivo T-cell depleted graft. Patients were stratified into cohorts based on ABO status (match, minor mismatch, major mismatch, bidirectional mismatch). Outcomes such as overall survival (OS), disease free survival (DFS), non-relapse mortality (NRM), relapse, incidence of acute graft versus host disease (GVHD), chronic GVHD, neutrophil engraftment, platelet engraftment and graft failure were evaluated. Survival analysis was done using Kaplan-Meier method and significant predictors were evaluated using Cox-proportional hazard regression method. Multivariate regression model included main effect (ABO status) and covariates (patient age, gender match, disease type, disease status, HCT-CI, Karnofsky performance status, donor type, conditioning intensity/use of TBI, stem cell source, GVHD prophylaxis, ATG/alemtuzumab use, transplant year). Results: Of 4946 patients who met the study criteria, 2741 patients (55.4%) were ABO matched, 1030 patients (20.8%) had minor ABO mismatch, 899 patients (18.1%) had major ABO mismatch and 276 patients (5.6%) had bidirectional ABO mismatch. Graft manipulation for ABO incompatibility was performed in 900 patients (minor ABO mismatch=532; major ABO mismatch=226; bidirectional mismatch=142), however, the information on individual graft manipulation techniques was limited. In multivariable analysis (table 1), major ABO mismatch significantly affected the OS, platelet engraftment and primary graft failure. Compared to ABO matched allo-HCT, major ABO mismatched allo-HCT was associated with worse OS (major mismatch - HR 1.16, 95% CI 1.05-1.29; p=0.005), inferior platelet engraftment (HR 0.83, 95% CI 0.77-0.90; p=<0.001), and higher risk of primary graft failure [4.5% (major mismatch) vs. 3.2% (ABO matched) - HR 1.60, 95% CI 1.12-2.30, p=0.01]. There was a significant interaction between the ABO status and graft type (peripheral blood vs. bone marrow) for the acute GVHD grades 2-4 model, and they are presented separately (table 1). Bidirectional ABO mismatch also significantly impacted the outcomes such as acute GVHD grades 2-4 (in bone marrow stem cell subgroup, HR 0.50, 95%CI 0.27-0.93, p=0.02) in addition to a trend towards inferior survival and NRM (p-value not significant). Other outcomes such as relapse (p=0.41), acute GVHD grades 3-4 (p=0.13), and chronic GVHD (p=0.30) were not significantly influenced by the ABO status. Conclusions: Our study demonstrates that pre-transplant ABO status is an independent predictor of survival and other post-transplant outcomes in a large cohort of patients with AML and ALL undergoing allo-HCT in the recent era. This demonstrates the importance of considering ABO status in the donor selection algorithms and potential strategies to mitigate its adverse impact. Due to the limited information available on graft manipulation strategies, the impact of graft manipulation techniques on the outcomes could not be evaluated and needs to be investigated in future studies. Figure 1 Figure 1. Disclosures Guru Murthy: Techspert: Consultancy; Guidepoint: Consultancy; Cancerexpertnow: Honoraria; Qessential: Consultancy; TG therapeutics: Other: Advisory board; Cardinal Health Inc.: Honoraria. Devine: Magenta Therapeutics: Current Employment, Research Funding; Tmunity: Current Employment, Research Funding; Sanofi: Consultancy, Research Funding; Johnsonand Johnson: Consultancy, Research Funding; Orca Bio: Consultancy, Research Funding; Be the Match: Current Employment; Vor Bio: Research Funding; Kiadis: Consultancy, Research Funding. Farhadfar: Incyte: Consultancy. Sharma: Vertex Pharmaceuticals/CRISPR Therapeutics: Other: Salary support paid to institution; Novartis: Other: Salary support paid to institution; Spotlight Therapeutics: Consultancy; Medexus Inc: Consultancy; CRISPR Therapeutics: Other, Research Funding; Vindico Medical Education: Honoraria. Stefanski: Novartis: Honoraria. Pulsipher: Equillium: Membership on an entity's Board of Directors or advisory committees; Adaptive: Research Funding; Jasper Therapeutics: Honoraria. Shaw: mallinkrodt: Other: payments; Orca bio: Consultancy.
Answer to December 2021 Photo Quiz
Eberly, Allison R. , Natarjan, Usha, Milone, Amber A., Lucke, Marisa A., Cañete‐Gibas, Connie , Wiederhold, Nathan P. , Wengenack, Nancy L. , Eberly, Allison R , Wiederhold, Nathan

Mayo Clinic

Journal of Clinical Microbiology | November 18, 2021 | Volume: 59 | Issue: 12 | Pages: No page available

10.1128/jcm.02899-20 | PMID 34792389 Get It

Photo Quiz: You Get What You Get, and Sometimes It’s Tuberculate
Eberly, Allison R. , Natarjan, Usha, Milone, Amber A., Lucke, Marisa A., Cañete‐Gibas, Connie , Wiederhold, Nathan P. , Wengenack, Nancy L. , Eberly, Allison R , Wiederhold, Nathan

Mayo Clinic

Journal of Clinical Microbiology | November 18, 2021 | Volume: 59 | Issue: 12 | Pages: No page available

10.1128/jcm.02897-20 | PMID 34792388 Get It

A Real-world Experience of Atrioventricular Synchronous Pacing with Leadless Ventricular Pacemakers
Kowlgi, Gurukripa N. , Tempel, Nathan D., Henrich, Mark, Venkatachalam, Kalpathi L., Scott, Luis R. , Shen, Win‐Kuang , Deshmukh, Abhishek , Madhavan, Malini , Lee, Hon-Chi , Friedman, Paul A. , Cha, Yong‐Mei , Mulpuru, Siva K. , Kowlgi, Narayan G , Tseng, Andrew S. , Asirvatham, Samuel J.

Mayo Clinic

No container title available | November 16, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163711930.05423871/v1 Get It

Aims: The MicraTM transcatheter pacing system (TPS) (Medtronic) is the only leadless pacemaker that promotes atrioventricular (AV) synchrony via accelerometer-based atrial sensing. Data regarding the real-world experience with this novel system are currently lacking. We sought to characterize patients undergoing MicraTM -AV implants, describe percentage AV synchrony achieved, and analyze the causes for suboptimal AV synchrony. Methods: In this retrospective cohort study, electronic medical records from 56 consecutive patients undergoing MicraTM -AV implants at the Mayo Clinic sites in Minnesota, Florida, and Arizona with a minimum follow-up of 3 months were reviewed. Demographic data, comorbidities, echocardiographic data, and clinical outcomes were compared among patients with and without atrial synchronous-ventricular pacing (AsVP) ≥70%. Results: Fifty-six percent of patients achieved AsVP ≥70%. Patients with adequate AsVP had smaller body mass indices, a lower proportion of congestive heart failure and pulmonary hypertension. Echocardiographic parameters and procedural characteristics were similar across the two groups. Active device troubleshooting was associated with higher AsVP. The likely reasons for low AsVP were persistent atrial arrhythmias, small A4-wave amplitude, and inadequate device reprogramming. Importantly, in patients with low AsVP, subjective clinical worsening was not noted during follow-up. Conclusion: With the increasing popularity of leadless PM, it is paramount for device implanting teams to be familiar with common predictors of AV synchrony and troubleshooting with MicraTM -AV devices.
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction
Givertz, Michael M. , Shah, Palak , McNulty, Steven E., Anstrom, Kevin J. , Mahr, Claudius , Gupta, Divya , Redfield, Margaret M. , Lala, Anuradha , Desvigne‐Nickens, Patrice , Braunwald, Eugene, Investigators, LIFE, Mohammed, Selma F. , Birru, Hellina, Aboye, Etsubdink, Lam, Phillip H. , Escobar, Nicole, Fink, Maria Cristina Domingues , Cappola, Thomas P. , Sheaffer, Wendy , Reilly, Bonitta, Ferree, J W, Ciezkowski, Gina, Herrera, Glenda, Mehta, Hirsch, Delucca, Rosemarie, Doddamani, Sanjay , Thomas, B. , Machen, Laurie, Kim, J., Christina, Athas, Lampert, Brent C. , Fontenelle, Cindy, Eiswirth, Clement, Rock, Darlene, Egnaczyk, Gregory F. , Rentas-Sherman, Enya, Barr, Deborah, Damato, Adrianna, Calayo, Christine, Herre, John M. , Carroll, Amanda , Keebler, Mary , Setliff, Bandaa, Gulati, Sanjeev , Winkler, K, Curtin, Laura, Ohmart, Carly, Halvorson, John, Mudd, James O., Camacho, S. Albert , Palardy, Maryse , Shah, Neha, Picardi, Kristina, Krishnamoorthy, Arun, Maximin, Adrienne, Horstmanshof, Douglas , Seiler, Beverly, Xu, Zi J., Mersola, S., Kransdorf, E. , Fonk, T., Oliveira, Guilherme H., Semenec, Terrence, Leo, Peter , Dunlap, Mark E. , Felker, G. Michael , Taylor, Lacey D., Sheehan, Mary, Levine, Sharon, Cocca-Spofford, Diane, Brooks, Liana, Cunningham, Thomas F., Acker, Nancy, Milbrandt, Susan, Gatzke, Janet, Dávila‐Román, Víctor G. , Bult, Karen, Weber, Elizabeth, Lesko, Mary, Mikhalkova, Deana , Fitzgerald, Kathleen, Whellan, David J. , Gutierrez, Jonathan, Goldsborough, Yavette, Caikauskaite, Indre, Skopicki, Hal A. , Huggins, Gordon S. , Yuen, Nathan, Haynes, Abbey, Katie, Carr, Snell, Gail, Smith, Andrew L. , Walker, Brandon S. , JOHNSON, J. Y. M., Henderson, Simmone, Pauwaa, Sunil, Bhat, Geetha , Gagliardi, A.R.T., Mann, Douglas L. , Vader, Justin M. , Starling, Randall C. , Margulies, Kenneth B. , Kiernan, Michael S. , Lewis, Gregory D. , DeVore, Adam D. , Hernandez, Adrian F. , Braunwald, Eugene , Investigators, LIFE, Aboye, Etsubdink A, Fink, Maria, Ferree, Jenny, Ravichandran, Ashwin Kumar , Herrera, Glenda, Kanwar, Manreet , Williams, Julie , Bhimaraj, Arvind , Lindenfeld, JoAnn , Gordon, Mary Ellen , Gulati, Sanjeev K., Winkler, Krystal, Tang, W.H. Wilson , Gorodeski, Eiran Z. , Norton, Nadine , Nichols, Julie, Taylor, Lacey, Cunningham, Thomas, Dirks, Anne, Wever‐Pinzon, Omar , Gilotra, Nisha A , Walker, Brandon, Henderson, Simmone, Gagliardi, Ann, Shah, Palak

Mayo Clinic

JAMA Cardiology | November 3, 2021 | Volume: 7 | Issue: 1 | Pages: 17

10.1001/jamacardio.2021.4567 | PMID 34730769 Get It

Modulation of dopamine release by ethanol is mediated by atypical GABAA receptors on cholinergic interneurons in the nucleus accumbens
Wadsworth, Hillary A. , Williams, Benjamin M. , Brundage, James , Hedges, David M. , Stockard, Alyssa , Jones, Stephen T., Arthur, Summer B., Hansen, David M., Schilaty, Nathan D. , Jang, Eun Young , Lee, Anna , Wallner, Martin , Yorgason, Jordan T , Lee, Anna M , Steffensen, Scott C , Stockard, Alyssa , Schilaty, Nathan D , Yorgason, Jordan T. , Anderson, Elizabeth J., Jones, Stephen T., Steffensen, Scott C.

Mayo Clinic

Addiction Biology | October 29, 2021 | Volume: 27 | Issue: 1 | Pages: No page available

10.1111/adb.13108 | PMID 34713509 Get It

AbstractPrevious studies indicate that moderate‐to‐high ethanol (EtOH) concentrations enhance dopamine (DA) neurotransmission in the mesolimbic DA system from the ventral tegmental area (VTA) and projecting to the nucleus accumbens core (NAc). However, voltammetry studies demonstrate that moderate‐to‐high EtOH concentrations decrease evoked DA release at NAc terminals. The involvement of γ‐aminobutyric acid (GABA) receptors (GABAARs), glycine (GLY) receptors (GLYRs) and cholinergic interneurons (CINs) in mediating EtOH inhibition of evoked NAc DA release were examined. Fast scan cyclic voltammetry, electrophysiology, optogenetics and immunohistochemistry techniques were used to evaluate the effects of acute and chronic EtOH exposure on DA release and CIN activity in C57/BL6, CD‐1, transgenic mice and δ‐subunit knockout (KO) mice (δ−/−). Ethanol decreased DA release in mice with an IC50 of 80 mM ex vivo and 2.0 g/kg in vivo. GABA and GLY decreased evoked DA release at 1–10 mM. Typical GABAAR agonists inhibited DA release at high concentrations. Typical GABAAR antagonists had minimal effects on EtOH inhibition of evoked DA release. However, EtOH inhibition of DA release was blocked by the α4β3δ GABAAR antagonist Ro15‐4513, the GLYR antagonist strychnine and by the GABA ρ1 (Rho‐1) antagonist TPMPA (10 μM) and reduced significantly in GABAAR δ−/− mice. Rho‐1 expression was observed in CINs. Ethanol inhibited GABAergic synaptic input to CINs from the VTA and enhanced firing rate, both of which were blocked by TPMPA. Results herein suggest that EtOH inhibition of DA release in the NAc is modulated by GLYRs and atypical GABAARs on CINs containing δ‐ and Rho‐subunits.
S1331 Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis
Samadder, N. Jewel , Foster, Nathan R. , Sanchez, Eduardo Vilar , Westover, Michelle, Della’Zanna, Gary , Rodriguez, Luz M. , Zahrieh, David M. , McMurray, Ryan P. , Burke, Carol A. , Stoffel, Elena M. , Kanth, Priyanka , Das, Rohit Kumar , Cruz‐Correa, Marcia , Richmond, Ellen S. , RODRIGUEZ, LUZ MARIA , Szabó, Éva , Limburg, Paul J.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S614-S614

10.14309/01.ajg.0000778856.64376.a8 Get It

S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection
Allegretti, Jessica R. , Kelly, Colleen , Louie, Thomas , Fisher, Monika, Hota, Susy , Misra, Bharat , Hise, Nicholas W. Van, Yen, Eugene F. , Facg, Bullock, Jeff S., Pullman, John, Nathan, Richard, Silverman, Michael , Davis, Ian, Khanna, Sahil , Pardi, Darrell S. , Orenstein, Robert , Grinspan, Ari , El‐Nachef, Najwa , Kraft, Colleen S., Budree, Shrish , Kassam, Zain , Bullock, Jeff S., Davis, Ian, McGill, Sarah , Kraft, Colleen S. , Borody, Thomas Julius

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S64

10.14309/01.ajg.0000773052.38150.f9 Get It